The transgenic animal platform for biopharmaceutical production

Transgenic Research
L R BertoliniJames D Murray

Abstract

The recombinant production of therapeutic proteins for human diseases is currently the largest source of innovation in the pharmaceutical industry. The market growth has been the driving force on efforts for the development of new therapeutic proteins, in which transgenesis emerges as key component. The use of the transgenic animal platform offers attractive possibilities, residing on the low production costs allied to high productivity and quality of the recombinant proteins. Although many strategies have evolved over the past decades for the generation of transgenic founders, transgenesis in livestock animals generally faces some challenges, mainly due to random transgene integration and control over transgene copy number. But new developments in gene editing with CRISPR/Cas system promises to revolutionize the field for its simplicity and high efficiency. In addition, for the final approval of any given recombinant protein for animal or human use, the production and characterization of bioreactor founders and expression patterns and functionality of the proteins are technical part of the process, which also requires regulatory and administrative decisions, with a large emphasis on biosafety. The approval of two mammary gland...Continue Reading

References

Jan 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·D V GoeddelA D Riggs
May 1, 1991·Journal of Biotechnology·M MassoudL M Houdebine
May 1, 1992·Bio/technology·M E SwansonJ S Logan
Sep 15, 1991·Experientia·S Rusconi
Jun 20, 1985·Nature·R E HammerR L Brinster
May 31, 1994·Journal of Biotechnology·L M Houdebine
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y YangJ M Wilson
Jan 1, 1993·Transgenic Research·C B WhitelawJ Clark
Apr 1, 1996·The American Journal of Clinical Nutrition·A Colman
Jul 1, 1997·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·P Yeh, M Perricaudet
Sep 26, 1997·Nature·I M Verma, N Somia
Dec 3, 1998·Research in Immunology·M W YoungM Harvey
May 20, 1999·Nature Biotechnology·A BaguisiY Echelard
Aug 26, 1999·Trends in Biotechnology·N S Rudolph
Oct 6, 1999·Current Opinion in Biotechnology·K BenihoudM Perricaudet
Nov 5, 1999·Nature Biotechnology·M K DyckF Pothier
Jan 29, 2000·Journal of Immunological Methods·D P PollockH M Meade
May 20, 2000·Journal of Mammary Gland Biology and Neoplasia·A J Clark
Dec 29, 2000·Transgenic Research·L M Houdebine
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·C J CohenJ M Bergelson
Mar 30, 2002·Nature Biotechnology·Alex J HarveyRobert Ivarie
Jul 31, 2002·Nature Biotechnology·Alan Dove
Aug 31, 2002·Journal of Dairy Science·W FanD E Kerr
Dec 17, 2002·Current Opinion in Biotechnology·Louis Marie Houdebine
Sep 2, 2003·Trends in Biotechnology·Michael K DyckMarc-André Sirard
May 30, 1953·Nature·J D WATSON, F H CRICK
Dec 4, 2003·Animal Reproduction Science·Heiner Niemann, Wilfried A Kues
Jul 24, 2004·Animal Reproduction Science·C L Keefer
Sep 14, 2004·Transgenic Research·Esmail BehboodiYann Echelard
Oct 19, 2005·Gene Therapy·R AlbaM Chillon
Dec 13, 2005·Journal of Biotechnology·Jorge R ToledoJosé A Cremata
Mar 11, 2006·The Journal of General Virology·Guohua YuGuoxiang Cheng
Jan 9, 2007·Protein Expression and Purification·Zeng-Sheng HanJian-Hong Hu
Jan 30, 2007·Proceedings of the National Academy of Sciences of the United States of America·S G LillicoH M Sang
Sep 18, 2007·Current Opinion in Biotechnology·Eva L Decker, Ralf Reski
Sep 19, 2007·Biotechnology Annual Review·Eric Soler, Louis-Marie Houdebine
Feb 5, 2008·Comparative Immunology, Microbiology and Infectious Diseases·Louis-Marie Houdebine
May 24, 2008·Journal of Bioscience and Bioengineering·Bo XiaoXu Bo Zhi
Aug 12, 2008·The Journal of Reproduction and Development·Ying ZhangEnkui Duan

❮ Previous
Next ❯

Citations

Feb 10, 2018·Journal of Animal Science and Biotechnology·Soo-Young YumGoo Jang
Oct 18, 2019·Protein and Peptide Letters·Muhammad Sarwar KhanGhulam Mustafa
Jan 30, 2018·Current Medicinal Chemistry·Nicolás E Núñez-NavarroFlavia C Zacconi
Apr 5, 2016·Oral Diseases·A Peterson
Dec 7, 2018·Nature Biotechnology·Gary Walsh
Oct 21, 2017·Reproduction in Domestic Animals = Zuchthygiene·I Lamas-ToranzoP Bermejo-Álvarez
Oct 4, 2017·Biotechnology and Applied Biochemistry·Malgorzata Kesik-Brodacka
Sep 16, 2018·Cell and Tissue Research·Melissa Shizue de A Yamashita, Eduardo O Melo
Jan 11, 2020·Frontiers in Bioengineering and Biotechnology·Nagesh K Tripathi, Ambuj Shrivastava
Dec 22, 2019·Biotechnology Advances·Jaber DehghaniYadollah Omidi
Jan 16, 2021·International Journal of Molecular Sciences·Tong ZhouZongbin Cui
Mar 12, 2021·Pharmacology Research & Perspectives·María L FormicaSantiago D Palma
Nov 12, 2016·Current Opinion in Biotechnology·Denise Marie Ney, Mark Raymond Etzel
Aug 18, 2021·International Journal of Biometeorology·Matheus Soares AlvesAirton Alencar de Araújo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.